Wedbush Reaffirms Their Buy Rating on Eiger Biopharmaceuticals (EIGR)


In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Eiger Biopharmaceuticals (EIGR), with a price target of $35. The company’s shares closed on Friday at $10.19.

According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.4% and a 28.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Currently, the analyst consensus on Eiger Biopharmaceuticals is a Strong Buy with an average price target of $28.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.33 and a one-year low of $8.40. Currently, Eiger Biopharmaceuticals has an average volume of 235.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts